CIK 0001775194 · Non-accelerated filer<br>Smaller reporting company
UPEXI, INC.
Sign in to watch- Ticker
- UPXI
- Exchange
- Nasdaq
- Industry
- Finance Services
- FY end
- Jun 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 833378978
- Phone
- 727-287-2800
- Business address
- 3030 N. ROCKY POINT DRIVE, SUITE 420, TAMPA, FL
- Former names
- GROVE, INC.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-07-16 | Dugan Lawrence Director | Grant or award | +50,000 | 51,389 | ||
| 2025-07-16 | Dugan Lawrence Director | Grant or award | +50,000 | 101,389 | ||
| 2025-07-16 | Dugan Lawrence Director | Purchase | +10,000 | $5.70 | $57K | 111,389 |
| 2025-07-16 | Dugan Lawrence Director | Purchase | +1,000 | $5.60 | $6K | 112,389 |
| 2025-07-16 | Williams Thomas Charles Director | Grant or award | +50,000 | 50,000 | ||
| 2025-07-16 | Williams Thomas Charles Director | Grant or award | +50,000 | 100,000 | ||
| 2025-07-16 | MARSHALL ALLAN Chief Executive Officer | Grant or award | +1,200,000 | 2,246,261 | ||
| 2025-07-16 | Norstrud Andrew James Chief Financial Officer | Grant or award | +250,000 | 409,138 | ||
| 2025-07-15 | Dugan Lawrence Director | Purchase | +1,000 | $5.17 | $5K | 1,389 |
| 2025-07-11 | Salkind Gene Director | Purchase | +20,243 | $4.94 | $100K | 385,370 |
| 2025-07-11 | MARSHALL ALLAN Chief Executive Officer | Purchase | +161,943 | $4.94 | $800K | 1,046,261 |
| 2025-04-17 | MARSHALL ALLAN Chief Executive Officer | Purchase | +657,895 | $2.28 | $1.5M | 809,318 |
| 2025-04-17 | MARSHALL ALLAN Chief Executive Officer | Grant or award | +75,000 | 884,318 | ||
| 2025-04-17 | MARSHALL ALLAN Chief Executive Officer | Grant or award · Warrants to purchase Common Stock | +500,000 | 500,000 | ||
| 2025-04-17 | Norstrud Andrew James Chief Financial Officer | Purchase 10b5-1 | +43,860 | $2.28 | $100K | 59,138 |
| 2025-04-17 | Norstrud Andrew James Chief Financial Officer | Grant or award 10b5-1 | +100,000 | 159,138 | ||
| 2025-04-17 | Salkind Gene Director | Purchase | +241,229 | $2.28 | $550K | 365,127 |
| 2025-04-17 | Salkind Gene Director | Grant or award · Options to buy common stock | +35,000 | 35,000 | ||
| 2025-03-12 | MARSHALL ALLAN Chief Executive Officer | Purchase · Convertible Preferred Stock | +125,000 | $2.60 | $325K | 125,000 |
| 2025-01-17 | Williams Thomas Charles Director | Grant or award · Options to buy common stock | +25,000 | 25,000 |
Page 2 of 4 · 74 trades